RVL Pharmaceuticals plc (RVLP)
$0.00
$0.00
(14.29%)
As on 22-Dec-2023 09:30EDT
Market cap
--
Revenue (TTM)
--
P/E Ratio
--
P/B Ratio
--
Div. Yield
--
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
--
-
ROE
--
-
ROCE
--
-
Industry P/E
--
-
EV/EBITDA
--
-
Debt to Equity
--
-
Book Value
--
-
EPS
--
-
Face value
--
-
Shares outstanding
--
7 Years Aggregate
CFO
$9.22 Mln
EBITDA
$82.68 Mln
Net Profit
$-691.11 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
RVL Pharmaceuticals (RVLP)
| -99.8 | -57.9 | -97.8 | -99.8 | -92.5 | -80.2 | -- |
|
BSE Sensex*
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
|---|---|
|
RVL Pharmaceuticals (RVLP)
| -99.8 |
|
S&P Small-Cap 600
| 13.9 |
|
BSE Sensex
| 18.7 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout RVL Pharmaceuticals (RVLP)
RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas... in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey. Read more
-
Chairman, Pres, CEO & Principal Financial Officer
Mr. Brian A. Markison
-
Chairman, Pres, CEO & Principal Financial Officer
Mr. Brian A. Markison
-
Headquarters
Bridgewater, NJ
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for RVL Pharmaceuticals (RVLP)
What is the current share price of RVL Pharmaceuticals plc (RVLP) Today?
The share price of RVL Pharmaceuticals plc (RVLP) is $0.00 (NASDAQ) as of 22-Dec-2023 09:30 EDT. RVL Pharmaceuticals plc (RVLP) has given a return of -92.53% in the last 3 years.
What is the current PB & PE ratio of RVL Pharmaceuticals plc (RVLP)?
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2022 |
-1.95 |
1.97 |
2021 |
-1.06 |
1.14 |
2020 |
-2.92 |
2.77 |
2019 |
-1.34 |
3.17 |
2018 |
-3.18 |
0.91 |
What is the 52 Week High and Low of RVL Pharmaceuticals plc (RVLP)?
The 52-week high and low of RVL Pharmaceuticals plc (RVLP) are Rs -- and Rs -- as of 06-Sep-2026.
What is the market cap of RVL Pharmaceuticals plc (RVLP)?
RVL Pharmaceuticals plc (RVLP) has a market capitalisation of $ 3 Mln as on 22-Dec-2023. As per SEBI classification, it is a Small Cap company.
Should I invest in RVL Pharmaceuticals plc (RVLP)?
Before investing in RVL Pharmaceuticals plc (RVLP), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.